CBC Group and Mubadala completed the acquisition of the Chinese neurology and allergy business of UCB for $680m.

CBC Group, Asia’s largest healthcare-dedicated asset management group, and Mubadala, the Abu Dhabi based investment company, completed the acquisition of the Chinese neurology and allergy business of UCB, a multinational biopharmaceutical company headquartered in Brussels, for $680m. "There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today's healthcare investing market," Fu Wei, CBC Group CEO.